ESKAP
Main information
- Trade name:
- ESKAP DPS
- Active ingredient:
- Noscapine,Sod.Cit.,Ammon.Chl.
- Available from:
- Kosha Lab.
- Dosage:
- 1.83,0.67,7;MG/1ML
- Pharmaceutical form:
- DPS
- Medicine domain:
- Humans
- Medicine type:
- Allopathic drug
Documents
- for the general public:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- for healthcare professionals:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for healthcare professionals.
Localization
- Available in:
-
India
- Language:
- English
Other information
Status
- Source:
- Central Drugs Standard Control Organization
- Last update:
- 09-08-2016
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- Access to this document is only available to registered users.
Register now for full access
13-2-2019
Jurnista (hydromorphone hydrochloride) prolonged-release
Product defect correction - potentially damaged tablets
Therapeutic Goods Administration - Australia
15-1-2019
Safety assessment of the substance, montmorillonite clay modified with hexadecyltrimethylammonium bromide, for use in food contact materials
Published on: Mon, 14 Jan 2019 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP) assessed the safety of montmorillonite clay modified with hexadecyltrimethylammonium bromide (HDTA) when used as an additive at up to ■■■■■ in polylactic acid (PLA) bottles intended for contact with water for long‐term storage at ambient temperature or below. The modified clay, which 90% w/w of the particles have a dimension of 33.1 μm or less and the average size is 9 μm, has a layered structure w...
Europe - EFSA - European Food Safety Authority EFSA Journal
28-11-2018
Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)
Update - medicine shortage
Therapeutic Goods Administration - Australia
20-11-2018
Peer review of the pesticide risk assessment of the active substance (EZ)‐1,3‐dichloropropene
Published on: Mon, 19 Nov 2018 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State, Spain, for the pesticide active substance (EZ)‐1,3‐dichloropropene are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the evaluation of the representative uses of (EZ)‐1,3‐dichloropropene ...
Europe - EFSA - European Food Safety Authority Publications
15-11-2018
Assessment of genetically modified maize MZHG0JG for food and feed uses, import and processing under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐DE‐2016‐133)
Published on: Wed, 14 Nov 2018 The scope of application EFSA‐GMO‐DE‐2016‐133 is for food and feed uses, import and processing of genetically modified (GM) maize MZHG0JG in the European Union. Maize MZHG0JG was developed to confer tolerance to the herbicidal active substances glyphosate and glufosinate‐ammonium. The molecular characterisation data and bioinformatic analyses do not identify issues requiring food/feed safety assessment. None of the identified differences in the agronomic/phenotypic and com...
Europe - EFSA - European Food Safety Authority Publications
8-11-2018
XOFIGO (radium Ra 223 dichloride) - Increased Incidence of Fractures and Trend for Increased Deaths with XOFIGO used in combination with abiraterone and prednisone/prednisolone
MedEffect Canada
6-11-2018
FDA Approves Experior for Reduction of Ammonia Gas Released from Beef Cattle Waste
FDA announced today the approval of Experior (lubabegron Type A medicated article), a beta-adrenergic agonist/antagonist drug that, when fed to beef cattle under specific conditions, results in less ammonia gas released as a by-product of their waste.
FDA - U.S. Food and Drug Administration
24-8-2018
Human medicines European public assessment report (EPAR): Gliolan, 5-aminolevulinic acid hydrochloride, Revision: 4, Authorised
Europe - EMA - European Medicines Agency
21-8-2018
Orphan designation: R)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride, for the: Treatment of hereditary angioedema
Europe - EMA - European Medicines Agency
3-8-2018
Human medicines European public assessment report (EPAR): Jentadueto, linagliptin / metformin hydrochloride, Revision: 14, Authorised
Europe - EMA - European Medicines Agency
3-8-2018
Human medicines European public assessment report (EPAR): Ameluz, 5-aminolevulinic acid hydrochloride, Revision: 12, Authorised
Europe - EMA - European Medicines Agency
3-8-2018
Human medicines European public assessment report (EPAR): Ristfor, sitagliptin / metformin hydrochloride, Revision: 18, Authorised
Europe - EMA - European Medicines Agency
1-8-2018
Human medicines European public assessment report (EPAR): Ceplene, histamine dihydrochloride, Revision: 12, Authorised
Europe - EMA - European Medicines Agency
24-7-2018
Opinion/decision on a Paediatric investigation plan (PIP): Palexia and associated names; Yantil and associated names; Tapentadol and associated names, Tapentadol (hydrochloride), Therapeutic area: Pain
Europe - EFSA - European Food Safety Authority EFSA Journal
24-7-2018
Orphan designation: Ambroxol hydrochloride, for the: Treatment of amyotrophic lateral sclerosis
Europe - EMA - European Medicines Agency
5-7-2018
Opinion/decision on a Paediatric investigation plan (PIP): Striverdi, Respimat, Olodaterol (hydrochloride), Therapeutic area: Pneumology-allergology
Europe - EFSA - European Food Safety Authority EFSA Journal
20-2-2019
Glibenclamide / metformin hydrochloride: List of nationally authorised medicinal products - PSUSA/00002002/201806
Glibenclamide / metformin hydrochloride: List of nationally authorised medicinal products - PSUSA/00002002/201806
Europe - EMA - European Medicines Agency
20-2-2019
Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/2018
Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/2018
Europe - EMA - European Medicines Agency
20-2-2019
Orphan designation: Histamine dihydrochloride, Treatment of acute myeloid leukaemia, 11/04/2005, Expired
Orphan designation: Histamine dihydrochloride, Treatment of acute myeloid leukaemia, 11/04/2005, Expired
Europe - EMA - European Medicines Agency
20-2-2019
Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0354/2018
Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0354/2018
Europe - EMA - European Medicines Agency
19-2-2019
Opinion/decision on a Paediatric investigation plan (PIP): Phenylephrine hydrochloride,ketorolac trometamol (OMS302), decision type: , therapeutic area: , PIP number: P/0362/2018
Opinion/decision on a Paediatric investigation plan (PIP): Phenylephrine hydrochloride,ketorolac trometamol (OMS302), decision type: , therapeutic area: , PIP number: P/0362/2018
Europe - EMA - European Medicines Agency
5-2-2019
Opinion/decision on a Paediatric investigation plan (PIP): Landiolol (hydrochloride), decision type: , therapeutic area: , PIP number: P/0273/2018
Opinion/decision on a Paediatric investigation plan (PIP): Landiolol (hydrochloride), decision type: , therapeutic area: , PIP number: P/0273/2018
Europe - EMA - European Medicines Agency
5-2-2019
Opinion/decision on a Paediatric investigation plan (PIP): Eviplera,emtricitabine,Rilpivirine (hydrochloride),Tenofovir (disoproxil fumarate), decision type: , therapeutic area: , PIP number: P/0274/2018
Opinion/decision on a Paediatric investigation plan (PIP): Eviplera,emtricitabine,Rilpivirine (hydrochloride),Tenofovir (disoproxil fumarate), decision type: , therapeutic area: , PIP number: P/0274/2018
Europe - EMA - European Medicines Agency
4-2-2019
Opinion/decision on a Paediatric investigation plan (PIP): Edurant,Rilpivirine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0322/2018
Opinion/decision on a Paediatric investigation plan (PIP): Edurant,Rilpivirine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0322/2018
Europe - EMA - European Medicines Agency
1-2-2019
Summary of opinion: Doxolipad,doxorubicin hydrochloride, 31/01/2019, Negative
Summary of opinion: Doxolipad,doxorubicin hydrochloride, 31/01/2019, Negative
Europe - EMA - European Medicines Agency
31-1-2019
Opinion/decision on a Paediatric investigation plan (PIP): Ciprofloxacin (hydrochloride), decision type: , therapeutic area: , PIP number: P/0253/2018
Opinion/decision on a Paediatric investigation plan (PIP): Ciprofloxacin (hydrochloride), decision type: , therapeutic area: , PIP number: P/0253/2018
Europe - EMA - European Medicines Agency
31-1-2019
Opinion/decision on a Paediatric investigation plan (PIP): Cariprazine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0301/2018
Opinion/decision on a Paediatric investigation plan (PIP): Cariprazine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0301/2018
Europe - EMA - European Medicines Agency
29-1-2019
Opinion/decision on a Paediatric investigation plan (PIP): Synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 (SOD1) messenger ribonucleic acid, decision type: , therapeutic area: , PIP number: P/0337/2018
Opinion/decision on a Paediatric investigation plan (PIP): Synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 (SOD1) messenger ribonucleic acid, decision type: , therapeutic area: , PIP number: P/0337/2018
Europe - EMA - European Medicines Agency
29-1-2019
Chlorphenoxamine hydrochloride : List of nationally authorised medicinal products - PSUSA/00010361/201805
Chlorphenoxamine hydrochloride : List of nationally authorised medicinal products - PSUSA/00010361/201805
Europe - EMA - European Medicines Agency
28-1-2019
Opinion/decision on a Paediatric investigation plan (PIP): Sarizotan (hydrochloride), decision type: , therapeutic area: , PIP number: P/0287/2018
Opinion/decision on a Paediatric investigation plan (PIP): Sarizotan (hydrochloride), decision type: , therapeutic area: , PIP number: P/0287/2018
Europe - EMA - European Medicines Agency
28-1-2019
Clomicalm (Elanco GmbH)
Clomicalm (Active substance: Clomipramine hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)720 of Mon, 28 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/000039/T/0030
Europe -DG Health and Food Safety
23-1-2019
Orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-, Treatment of diffuse large B-cell lymphoma, 27/06/2016, Positive
Orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-, Treatment of diffuse large B-cell lymphoma, 27/06/2016, Positive
Europe - EMA - European Medicines Agency
22-1-2019
Orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes), Treatment of hepatocellular carcinoma, 23/02/2011, Positive
Orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes), Treatment of hepatocellular carcinoma, 23/02/2011, Positive
Europe - EMA - European Medicines Agency
16-1-2019
EU/3/18/2125 (Isabelle Ramirez)
EU/3/18/2125 (Active substance: Benserazide hydrochloride) - Orphan designation - Commission Decision (2019)221 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000001719
Europe -DG Health and Food Safety
16-1-2019
EU/3/10/833 (FGK Representative Service GmbH)
EU/3/10/833 (Active substance: Doxorubicin hydrochloride (in heat-sensitive liposomes)) - Transfer of orphan designation - Commission Decision (2019)237 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003113
Europe -DG Health and Food Safety
16-1-2019
EU/3/16/1672 (Celgene Europe B.V.)
EU/3/16/1672 (Active substance: 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride) - Transfer of orphan designation - Commission Decision (2019)236 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003283
Europe -DG Health and Food Safety
11-1-2019
Opinion/decision on a Paediatric investigation plan (PIP): Octenidine (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0240/2018
Opinion/decision on a Paediatric investigation plan (PIP): Octenidine (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0240/2018
Europe - EMA - European Medicines Agency
13-12-2018
Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)
Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)
Europe - EMA - European Medicines Agency
13-12-2018
Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance
Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance
Europe - EMA - European Medicines Agency
11-12-2018
Epinephrine mepivacaine hydrochloride, mepivacaine norepinephrine, mepivacaine: List of nationally authorised medicinal products - PSUSA/00001979/201803
Epinephrine mepivacaine hydrochloride, mepivacaine norepinephrine, mepivacaine: List of nationally authorised medicinal products - PSUSA/00001979/201803
Europe - EMA - European Medicines Agency
28-11-2018
Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0177/2018
Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0177/2018
Europe - EMA - European Medicines Agency
28-11-2018
Opinion/decision on a Paediatric investigation plan (PIP): Mexiletine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0210/2018
Opinion/decision on a Paediatric investigation plan (PIP): Mexiletine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0210/2018
Europe - EMA - European Medicines Agency
28-11-2018
Econor (Elanco GmbH)
Econor (Active substance: Valnemulin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8038 of Wed, 28 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/42/T/54
Europe -DG Health and Food Safety
28-11-2018
Opinion/decision on a Paediatric investigation plan (PIP): ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-gu
Opinion/decision on a Paediatric investigation plan (PIP): ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-guanidino-1-hexanone hexahydrochloride, decision type: , therapeutic area: , PIP number: P/0134/2018
Europe - EMA - European Medicines Agency
28-11-2018
Opinion/decision on a Paediatric investigation plan (PIP): naloxone (hydrochloride), decision type: , therapeutic area: , PIP number: P/0146/2018
Opinion/decision on a Paediatric investigation plan (PIP): naloxone (hydrochloride), decision type: , therapeutic area: , PIP number: P/0146/2018
Europe - EMA - European Medicines Agency
27-11-2018
Opinion/decision on a Paediatric investigation plan (PIP): (R)-2-amino-3-phenylpropylcarbamate hydrochloride (solriamfetol), decision type: , therapeutic area: , PIP number: P/0207/2018
Opinion/decision on a Paediatric investigation plan (PIP): (R)-2-amino-3-phenylpropylcarbamate hydrochloride (solriamfetol), decision type: , therapeutic area: , PIP number: P/0207/2018
Europe - EMA - European Medicines Agency
26-11-2018
Wakix (Bioprojet Pharma)
Wakix (Active substance: Pitolisant hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7974 of Mon, 26 Nov 2018
Europe -DG Health and Food Safety
13-11-2018
EU/3/17/1836 (Zogenix GmbH)
EU/3/17/1836 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7576 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/233/16/T/01
Europe -DG Health and Food Safety
13-11-2018
EU/3/13/1219 (Zogenix GmbH)
EU/3/13/1219 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7575 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/140/13/T/01
Europe -DG Health and Food Safety
1-11-2018
Dexdomitor (Orion Corporation)
Dexdomitor (Active substance: dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7380 of Thu, 01 Nov 2018
Europe -DG Health and Food Safety
31-10-2018
Evista (Daiichi Sankyo Europe GmbH)
Evista (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7342 of Wed, 31 Oct 2018
Europe -DG Health and Food Safety
26-9-2018
Sileo (Orion Corporation)
Sileo (Active substance: Dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)6325 of Wed, 26 Sep 2018
Europe -DG Health and Food Safety
18-9-2018
Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/201801
Europe - EMA - European Medicines Agency
10-9-2018
Phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010430/201711
Europe - EMA - European Medicines Agency
10-9-2018
Ciprofloxacin hydrochloride / hydrocortisone: List of nationally authorised medicinal products - PSUSA/00000774/201711
Europe - EMA - European Medicines Agency
10-8-2018
Brinavess (Correvio)
Brinavess (Active substance: vernakalant hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5523 of Fri, 10 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1215/T/31
Europe -DG Health and Food Safety
30-7-2018
Segluromet (Merck Sharp and Dohme B.V.)
Segluromet (Active substance: ertugliflozin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5103 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4314/T/2
Europe -DG Health and Food Safety
30-7-2018
Ceplene (Noventia Pharma Srl)
Ceplene (Active substance: Histamine dihydrochloride) - Centralised - Renewal - Commission Decision (2018)5116 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/796/R/36
Europe -DG Health and Food Safety
27-7-2018
EU/3/06/401 (Pfizer Europe MA EEIG)
EU/3/06/401 (Active substance: N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium; 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate) - Transfer of orphan designation - Commission Decision (2018)5038 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/032/06/T/03
Europe -DG Health and Food Safety
23-7-2018
Optruma (Eli Lilly Nederland B.V.)
Optruma (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4893 of Mon, 23 Jul 2018
Europe -DG Health and Food Safety
12-7-2018
Econor (Elanco Europe Ltd)
Econor (Active substance: Valnemulin hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4580 of Thu, 12 Jul 2018
Europe -DG Health and Food Safety
11-7-2018
Ariclaim (Eli Lilly Nederland B.V.)
Ariclaim (Active substance: duloxetine hydrochloride) - Centralised - Withdrawal - Commission Decision (2018)4515 of Wed, 11 Jul 2018
Europe -DG Health and Food Safety
10-7-2018
Ammonaps (Swedish Orphan Biovitrum International AB)
Ammonaps (Active substance: Sodium phenylbutyrate) - Centralised - Yearly update - Commission Decision (2018)4483 of Tue, 10 Jul 2018
Europe -DG Health and Food Safety
5-7-2018
Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open
This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.
Europe - EMA - European Medicines Agency